A study by Antoine et al. suggested that the deregulation of Erb-B2 Receptor Tyrosine Kinase 4 (ERBB4)-SRC signaling might be the reason underlying the pathogenesis of Group 4 medulloblastoma, where the authors found increased tyrosine kinase phosphorylation, predominantly ERBB4, and the increased expression of SRC and its downstream targets [37]. The gene discussed is SRC; the disease is medulloblastoma.